AstraZeneca hit by drug failureShares in Anglo-Swedish drug have closed down 8% in UK trade after the failure of its Iressa drug in a major clinical trial. The lung cancer drug did not significantly prolong survival in patients with the disease. Meanwhile, another of its major money spinners - cholesterol drug Crestor - is facing mounting safety concerns. "I am determined to improve our development and regulatory performance, restore confidence in the company and value to shareholders," said chief executive Tom McKillop. AztraZeneca has now appointed a new executive director to the board.